Issn Print: 0923-7534
Publication Date: 2017/10/01
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced : a phase 3, open-label, randomized studyEGFR: a phase 3, open-label, randomized study mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Y. K. Shi; L. Wang; B. H. Han; W. Li; P. Yu; Y. P. Liu; C. M. Ding; X. Song; Z. Y. Ma; X. L. Ren; J. F. Feng; H. L. Zhang; G. Y. Chen; X. H. Han; N. Wu; C. Yao; Y. Song; S. C. Zhang; W. Song; X. Q. Liu; S. J. Zhao; Y. C. Lin; X. Q. Ye; K. Li; Y. Q. Shu; L. M. Ding; F. L. Tan; Y. Sun
Author Information: Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.